"To conclude, by leveraging an unconventional spli
Post# of 151984
(Total Views: 437)
Posted On: 04/28/2025 11:22:48 AM
"To conclude, by leveraging an unconventional splicing mechanism during UPR, we developed an RNA-based gene switch to control expression from delivered nucleic acids (mRNA or DNA) encoding ER stress causing proteins. Further testing and refinement of XBP1F modified therapeutic constructs in animal models with the goal of developing mRNA and gene therapies with decreased immunotoxicity and improved safety profiles is underway.”
Summary:
At the upcoming ASGCT (American Society of Gene and Cell Therapy) meeting on May 14, researchers from Duke University, led by Roza Ogurlu, will present major new technology that directly involves leronlimab.
They developed a novel RNA-based gene switch that controls how much protein (like leronlimab) is produced inside cells.
This switch uses the cell’s own unfolded protein response (UPR) to reduce ER stress and prevent toxicity during gene therapy or mRNA therapy delivery.
Critically, they specifically tested leronlimab using this technology:
• Resulted in lower ER stress.
• Stabilized expression levels.
• Reduced immune activation and toxicity.
• Proved effective in cell lines and animal models (mice).
This breakthrough could dramatically improve leronlimab’s safety profile, durability, and effectiveness — opening the door for safer use in mRNA therapies, AAV gene therapies, cancer treatments, autoimmune conditions, and beyond.
Potentially, with the help of AI-based partners like Dyno Therapeutics (who specialize in designing optimal delivery vectors), leronlimab could become part of a new generation of cell and gene therapies with vastly superior performance and safety.
This development has not yet been widely publicized but it represents a critical step forward for Cytodyn’s future, if properly leveraged."
Riz, what a fantastic find! I wonder if this explains why our CRC trial has not been moving forward? Certainly, this could change our one bite from the apple. Additionally, it would explain the silence. This changes everything!
Summary:
At the upcoming ASGCT (American Society of Gene and Cell Therapy) meeting on May 14, researchers from Duke University, led by Roza Ogurlu, will present major new technology that directly involves leronlimab.
They developed a novel RNA-based gene switch that controls how much protein (like leronlimab) is produced inside cells.
This switch uses the cell’s own unfolded protein response (UPR) to reduce ER stress and prevent toxicity during gene therapy or mRNA therapy delivery.
Critically, they specifically tested leronlimab using this technology:
• Resulted in lower ER stress.
• Stabilized expression levels.
• Reduced immune activation and toxicity.
• Proved effective in cell lines and animal models (mice).
This breakthrough could dramatically improve leronlimab’s safety profile, durability, and effectiveness — opening the door for safer use in mRNA therapies, AAV gene therapies, cancer treatments, autoimmune conditions, and beyond.
Potentially, with the help of AI-based partners like Dyno Therapeutics (who specialize in designing optimal delivery vectors), leronlimab could become part of a new generation of cell and gene therapies with vastly superior performance and safety.
This development has not yet been widely publicized but it represents a critical step forward for Cytodyn’s future, if properly leveraged."
Riz, what a fantastic find! I wonder if this explains why our CRC trial has not been moving forward? Certainly, this could change our one bite from the apple. Additionally, it would explain the silence. This changes everything!
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼